<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534129</url>
  </required_header>
  <id_info>
    <org_study_id>ProTechSure 001</org_study_id>
    <nct_id>NCT02534129</nct_id>
  </id_info>
  <brief_title>Topical Use of Difinsa53™ to Prevent Radiation Dermatitis</brief_title>
  <official_title>Topical Use of a Silibin-based Cream, Difinsa53™, to Prevent Radiation Dermatitis in Patients With Breast Cancer: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProTechSure Scientific, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Poudre Valley Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProTechSure Scientific, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial of the silibin containing cream, Difinsa53 to determine efficacy in delaying,
      ameliorating, or preventing radiation dermatitis in patients with breast cancer undergoing
      whole breast radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study seeks to evaluate the efficacy of DIFINISA53™, a safe silibin-based skin
      cream, on preventing radiation dermatitis (RD) when compared to an over the counter ointment,
      Aquaphor, in women undergoing radiation therapy for breast cancer following lumpectomy or
      mastectomy surgery. Presently there is no known fully effective topical protectant from RD
      and there is no consensus among radiation oncologists on how best to treat RD. This study
      seeks to identify a more effective option for patients receiving radiation therapy. Each
      participant will apply the DIFINISA53™ cream to one area of the treated skin and Aquaphor to
      another area of treated skin. Skin reactions will be evaluated using medical professional
      assessment, participant assessment, and photographic assessment by a third party.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient dermatitis was seen in the controls to allow any determination of protection by
    Difinsa53
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation Dermatitis as Determined by Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria</measure>
    <time_frame>8 weeks</time_frame>
    <description>A blinded observer will quantify degree of dermatitis assigning each half of the radiation field a score from 0 to 4. 0 represents no dermatitis and 4 is severe dermatitis using the RTOG scoring criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Radiodermatitis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difinsa53</intervention_name>
    <description>Difinsa53 cream is applied to one half of radiation field</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Dimethicone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aquaphor</intervention_name>
    <description>Aquaphor is applied to one half of radiation field</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>petrolatum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients 18 years and older

          -  Pathologic diagnosis of breast cancer requiring radiation therapy to whole breast

          -  Able to apply lotion to treatment area at least twice daily during radiation course

          -  All surgical sites healed

          -  No evidence of infection

          -  No history of sensitivity to any component in Aquaphor or Difensa53

        Exclusion Criteria:

          -  Prior history of radiation therapy (RT) to that site

          -  Known dermatologic conditions affecting skin in radiation port

          -  Concurrent chemotherapy

          -  Skin infection in radiation port

          -  History of sensitivity to Aquaphor or Difensa53 component
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Petit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Health, Poudre Valley Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Poudre Valley Health System</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011 May;27(2):e1-17. doi: 10.1016/j.soncn.2011.02.009.</citation>
    <PMID>21514477</PMID>
  </reference>
  <reference>
    <citation>Becker-Schiebe M, Mengs U, Schaefer M, Bulitta M, Hoffmann W. Topical use of a silymarin-based preparation to prevent radiodermatitis : results of a prospective study in breast cancer patients. Strahlenther Onkol. 2011 Aug;187(8):485-91. doi: 10.1007/s00066-011-2204-z. Epub 2011 Jul 22.</citation>
    <PMID>21786113</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>October 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2017</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>radiation</keyword>
  <keyword>dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>13 patients were entered, each of whom had a single radiation port divided into two fields. One received aquaphor protection and the other received Difinsa53 protection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aquaphor</title>
          <description>This radiation field treated with aquaphor</description>
        </group>
        <group group_id="P2">
          <title>Difinsa53</title>
          <description>This radiation field treated with Difinsa53</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population consisted of 13 breast cancer patients receiving radiation to a breast. Each breast was divided into two radiation fields, one defined as the Difinsa53 arm and the other as the Aquaphor Arm. Thus each participant contributed data from two fields.</population>
      <group_list>
        <group group_id="B1">
          <title>Difinsa53 and Aquaphor Arms</title>
          <description>Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
Difinsa53: Difinsa53 cream is applied to one half of radiation field
Aquaphor: Aquaphor is applied to one half of radiation field</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Participants</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiation Dermatitis as Determined by Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria</title>
        <description>A blinded observer will quantify degree of dermatitis assigning each half of the radiation field a score from 0 to 4. 0 represents no dermatitis and 4 is severe dermatitis using the RTOG scoring criteria.</description>
        <time_frame>8 weeks</time_frame>
        <population>All patients were analyzed by blinded observor</population>
        <group_list>
          <group group_id="O1">
            <title>Difinsa 53 Arm</title>
            <description>Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
Difinsa53: Difinsa53 cream is applied to one half of radiation field</description>
          </group>
          <group group_id="O2">
            <title>Aquaphor Arm</title>
            <description>Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
Aquaphor: Aquaphor is applied to one half of radiation field</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Dermatitis as Determined by Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria</title>
          <description>A blinded observer will quantify degree of dermatitis assigning each half of the radiation field a score from 0 to 4. 0 represents no dermatitis and 4 is severe dermatitis using the RTOG scoring criteria.</description>
          <population>All patients were analyzed by blinded observor</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected over 12 weeks for each arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Difinsa53 Arm</title>
          <description>Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
Difinsa53: Difinsa53 cream is applied to one half of radiation field</description>
        </group>
        <group group_id="E2">
          <title>Aquaphor Arm</title>
          <description>Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
Aquaphor: Aquaphor is applied to one half of radiation field</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was terminated early, based on minimal radiation dermatitis (scores of 0-1 only in most fields evaluated) that precluded any meaningful analysis of any differing effect in the two treatment arms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>L. Michael Glode, MD</name_or_title>
      <organization>ProTechSure Scientific Inc.</organization>
      <phone>303-526-9031</phone>
      <email>mike.glode@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

